BioArctic (BIOA) Q4 2025 earnings summary

Executive summary

• Achieved record financial results in 2025, marking a transformative year with significant revenue and profit growth, driven by strong demand for Leqembi and expansion of the innovation pipeline.

• Leqembi established as a leading Alzheimer's treatment, approved in 53 countries, with expanded indications, new formulations, and significant regulatory progress.

• Broadened pipeline with new projects in Parkinson's, Huntington's, ALS, and two new candidate drug nominations in Q4.

• Entered and expanded strategic partnerships with Eisai, Bristol Myers Squibb, and Novartis, enhancing financial and R&D capabilities.

• Strong financial position enabled continued investment in R&D and a proposed dividend of SEK 2 per share.

Financial highlights

• Full-year 2025 net revenues reached SEK 2.0 billion, an increase of ~700% year-over-year, with recurring revenues of SEK 520 million.

• Q4 net revenues were SEK 184 million, with SEK 127 million in royalties and SEK 51 million from Novartis upfront payments.

• Operating profit for the year was SEK 1,258.8 million, with a strong cash position of SEK 2.2 billion at year-end.

• Board proposed a dividend of SEK 2 per share.

• Q4 operating profit was SEK 33 million, reversing a prior year loss.

Outlook and guidance

• Expectation of continued strong Leqembi sales growth, with Eisai on track to meet its JPY 76.5 billion sales forecast.

• Operating expenses projected to increase by 50%-70% in 2026 as the project portfolio expands.

• Anticipation of commercial milestones from Eisai in 2026, with outstanding milestones totaling EUR 54 million.

• Dividend payments expected to continue, subject to board approval.

• The company aims to continue investing in R&D and pursue new strategic partnerships.